journal.pone.0102987.pdf (295.02 kB)
Download file

Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability

Download (295.02 kB)
journal contribution
posted on 04.06.2015, 14:02 by Chris Newby, L. G. Heaney, A. Menzies-Gow, R. M. Niven, A. Mansur, C. Bucknall, R. Chaudhuri, J. Thompson, P. Burton, Chris Brightling, British Thoracic Society Severe Refractory Asthma Network
Background: Severe refractory asthma is a heterogeneous disease. We sought to determine statistical clusters from the British Thoracic Society Severe refractory Asthma Registry and to examine cluster-specific outcomes and stability. Methods: Factor analysis and statistical cluster modelling was undertaken to determine the number of clusters and their membership (N = 349). Cluster-specific outcomes were assessed after a median follow-up of 3 years. A classifier was programmed to determine cluster stability and was validated in an independent cohort of new patients recruited to the registry (n = 245). Findings: Five clusters were identified. Cluster 1 (34%) were atopic with early onset disease, cluster 2 (21%) were obese with late onset disease, cluster 3 (15%) had the least severe disease, cluster 4 (15%) were the eosinophilic with late onset disease and cluster 5 (15%) had significant fixed airflow obstruction. At follow-up, the proportion of subjects treated with oral corticosteroids increased in all groups with an increase in body mass index. Exacerbation frequency decreased significantly in clusters 1, 2 and 4 and was associated with a significant fall in the peripheral blood eosinophil count in clusters 2 and 4. Stability of cluster membership at follow-up was 52% for the whole group with stability being best in cluster 2 (71%) and worst in cluster 4 (25%). In an independent validation cohort, the classifier identified the same 5 clusters with similar patient distribution and characteristics. Interpretation: Statistical cluster analysis can identify distinct phenotypes with specific outcomes. Cluster membership can be determined using a classifier, but when treatment is optimised, cluster stability is poor.

Funding

Asthma UK, AirPROM FP7, CB is supported by a Wellcome Senior Clinical Fellowship, pilot funding for the Registry was provided as unrestricted research grants from Astra Zeneca, Glaxo Smith Kline and Novartis.

History

Citation

PLoS One, 2014, 9 (7), p. e102987

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Infection, Immunity and Inflammation

Version

VoR (Version of Record)

Published in

PLoS One

Publisher

Public Library of Science

issn

1932-6203

eissn

1932-6203

Copyright date

2014

Available date

04/06/2015

Publisher version

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0102987

Notes

PMCID: PMC4109965

Language

en